Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Feb 11:352:i438.
doi: 10.1136/bmj.i438.

Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials

Sripal Bangalore  1 , Robert Fakheri  2 , Bora Toklu  3 , Franz H Messerli  4
Affiliations
Meta-Analysis

Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials

Sripal Bangalore et al. BMJ. .

Erratum in

Abstract

Objective: To evaluate the outcomes with use of renin angiotensin system (RAS) blockers compared with other antihypertensive agents in people with diabetes.

Design: Meta-analysis.

Data sources and study selection: PubMed, Embase, and the Cochrane central register of controlled trials databases for randomized trials of RAS blockers versus other antihypertensive agents in people with diabetes mellitus. Outcomes were death, cardiovascular death, myocardial infarction, angina, stroke, heart failure, revascularization, and end stage renal disease.

Results: The search yielded 19 randomized controlled trials that enrolled 25,414 participants with diabetes for a total of 95,910 patient years of follow-up. When compared with other antihypertensive agents, RAS blockers were associated with a similar risk of death (relative risk 0.99, 95% confidence interval 0.93 to 1.05), cardiovascular death (1.02, 0.83 to 1.24), myocardial infarction (0.87, 0.64 to 1.18), angina pectoris (0.80, 0.58 to 1.11), stroke (1.04, 0.92 to 1.17), heart failure (0.90, 0.76 to 1.07), and revascularization (0.97, 0.77 to 1.22). There was also no difference in the hard renal outcome of end stage renal disease (0.99, 0.78 to 1.28) (power of 94% to show a 23% reduction in end stage renal disease).

Conclusions: In people with diabetes, RAS blockers are not superior to other antihypertensive drug classes such as thiazides, calcium channel blockers, and β blockers at reducing the risk of hard cardiovascular and renal endpoints. These findings support the recommendations of the guidelines of the European Society of Cardiology/European Society of Hypertension and eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure to also use other antihypertensive agents in people with diabetes but without kidney disease.

PubMed Disclaimer

Figures

None
Fig 1 Outcomes of death with renin angiotensin system (RAS) blockers compared with other antihypertensives in people with diabetes
None
Fig 2 Outcome of cardiovascular death with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 3 Outcome of myocardial infarction with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 4 Outcome of angina pectoris with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 5 Outcome of stroke with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 6 Outcome of heart failure with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 7 Outcome of revascularization with renin angiotensin system (RAS) compared with antihypertensives in people with diabetes
None
Fig 8 Outcome of end stage renal disease with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 9 Outcome of drug withdrawal owing to adverse effects with renin angiotensin system (RAS) compared with other antihypertensives in people with diabetes
None
Fig 10 Outcomes with renin angiotensin system (RAS) compared with calcium channel blockers in people with diabetes
None
Fig 11 Outcomes with renin angiotensin system (RAS) compared with diuretics in people with diabetes
None
Fig 12 Outcomes with renin angiotensin system (RAS) compared with β blockers in people with diabetes
See this image and copyright information in PMC

Comment in

  • Dtsch Med Wochenschr. 2016 Apr;141(8):527-8

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993;16:1022-5. 10.2337/diacare.16.7.1022. 8359095. - DOI - PubMed
    1. Standards of medical care in diabetes–2015: summary of revisions. Diabetes Care 2015;38(Suppl 1):S4 10.2337/dc15-S003. . - DOI - PubMed
    1. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014;32:3-15. 10.1097/HJH.0000000000000065. 24270181. - DOI - PubMed
    1. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(Suppl 2):S12-154. 10.1053/j.ajkd.2006.12.005. 17276798. - DOI - PubMed
    1. Mancia G, Fagard R, Narkiewicz K, et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31:1281-357. 10.1097/01.hjh.0000431740.32696.cc. 23817082. - DOI - PubMed

MeSH terms

Substances